The Annals of pharmacotherapy
-
Meta Analysis
Meta-analysis of the Efficacy and Safety of Secukinumab for the Treatment of Plaque Psoriasis.
In January 2015, US FDA approved secukinumab, a human interleukin-17A (IL-17A) antagonist, for the treatment of plaque psoriasis. ⋯ Meta-analysis of the seven Phase III clinical trials resulted in superiority of secukinumab over etanercept in terms of the efficacy and safety. However, long-term safety data is lacking at this time so post-marketing surveillance should be performed for any adverse events associated with the use of this new biological medication.